JAN 27, 2017
Abbott has reported a net gain of $4.4 billion in 2016, up 68.4% from $1.4 billion in 2015.
Release of the Tencis Symfony IOL – the first toric and non-toric extended range of vision IOL approved in the US – drove the financial growth, says Abbott, boosting medical optics operational sales by 6.9%.
Worldwide sales in the fourth quarter showed a 2.8% increase on a reported basis (revenue minus expenses) and a 3.8% increase on an operational basis (operating revenue minus operating expenses) from the same quarter of 2015.
The company’s full year sales were $20.9 billion, 2.2% more and 4.8% more on reported and operational earnings, respectively, compared with 2015.